Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LF-1
- Development stage
- Preclinical
- Lead developer
- Fudan University
- Modality
- Peptides
- Administration
- Topical
01
Overview
LF-1 is a synthetic lactotransferrin-derived antimicrobial peptide designed based on the N-terminal functional sequence of lactotransferrin (specifically lactoferrampin). It exhibits selective antibacterial and antibiofilm activity against the cariogenic bacterium Streptococcus mutans. LF-1 acts by disrupting the bacterial cell membrane, altering membrane potential and hydrophobicity, and downregulating virulence-associated genes involved in acidogenicity, aciduricity, and extracellular polysaccharide synthesis. It has demonstrated efficacy in reducing dental caries in rodent models and is being developed for the prevention and control of dental caries.
- Other names
- WKLLRKAWKLLRKAlactotransferrin-derived antimicrobial peptide LF-1
Beyond the preview
Go deeper on LF-1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LF-1.